<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Clin Mol Hepatol</journal-id>
      <journal-id journal-id-type="iso-abbrev">Clin Mol Hepatol</journal-id>
      <journal-id journal-id-type="publisher-id">CMH</journal-id>
      <journal-title-group>
        <journal-title>Clinical and Molecular Hepatology</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">2287-2728</issn>
      <issn pub-type="epub">2287-285X</issn>
      <publisher>
        <publisher-name>The Korean Association for the Study of the Liver</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">25320735</article-id>
      <article-id pub-id-type="pmc">4197180</article-id>
      <article-id pub-id-type="doi">10.3350/cmh.2014.20.3.306</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>A synchronous hepatocellular carcinoma and renal cell carcinoma treated with radio-frequency ablation</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Lee</surname>
            <given-names>Yoon Serk</given-names>
          </name>
          <xref ref-type="aff" rid="A1"/>
        </contrib>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Kim</surname>
            <given-names>Jeong Han</given-names>
          </name>
          <xref ref-type="aff" rid="A1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Yoon</surname>
            <given-names>Hyeon Young</given-names>
          </name>
          <xref ref-type="aff" rid="A1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Choe</surname>
            <given-names>Won Hyeok</given-names>
          </name>
          <xref ref-type="aff" rid="A1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Kwon</surname>
            <given-names>So Young</given-names>
          </name>
          <xref ref-type="aff" rid="A1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Lee</surname>
            <given-names>Chang Hong</given-names>
          </name>
          <xref ref-type="aff" rid="A1"/>
        </contrib>
      </contrib-group>
      <aff id="A1">Department of Internal Medicine, Konkuk University School of Medicine, Seoul, Korea.</aff>
      <author-notes>
        <corresp>Corresponding author: Jeong Han Kim. Department of Internal Medicine, Konkuk University School of Medicine, 120-1 Neungdong-ro, Gwangjin-gu, Seoul 143-729, Korea. Tel:+82-2-2030-7764, Fax: +82-2-2030-5029, <email>93haan@hanmail.net</email></corresp>
      </author-notes>
      <pub-date pub-type="ppub">
        <month>9</month>
        <year>2014</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>25</day>
        <month>9</month>
        <year>2014</year>
      </pub-date>
      <volume>20</volume>
      <issue>3</issue>
      <fpage>306</fpage>
      <lpage>309</lpage>
      <history>
        <date date-type="received">
          <day>16</day>
          <month>11</month>
          <year>2012</year>
        </date>
        <date date-type="rev-recd">
          <day>21</day>
          <month>12</month>
          <year>2012</year>
        </date>
        <date date-type="accepted">
          <day>14</day>
          <month>1</month>
          <year>2013</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>Copyright &#xA9; 2014 by The Korean Association for the Study of the Liver</copyright-statement>
        <copyright-year>2014</copyright-year>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">
          <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">http://creativecommons.org/licenses/by-nc/3.0/</ext-link>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>Radio-frequency ablation (RFA) is a curative treatment for hepatocellular carcinoma (HCC). Percutaneous RFA has been shown to be beneficial for patients with small renal cell carcinoma (RCC) lacking indications for resection. We experienced the case of a 53-year-old male who had conditions that suggested HCC, RCC, and alcoholic liver cirrhosis. Abdominal contrast-enhanced computed tomography (CT) and magnetic resonance image showed liver cirrhosis with 2.8 cm ill-defined mass in segment 2 of the liver and 1.9 cm hypervascular mass in the left kidney. These findings were compatible with the double primary cancers of HCC and RCC. Transarterial chemoembolization (TACE) was performed to treat the HCC. After the TACE, a focal lipiodol uptake defect was noticed on a follow up CT images and loco-regional treatment was recommended. Therefore, we performed RFAs to treat HCC and RCC. There was no evidence of recurrence in the follow up image after 1 month.</p>
      </abstract>
      <kwd-group>
        <kwd>Hepatocellular carcinoma</kwd>
        <kwd>Renal cell carcinoma</kwd>
        <kwd>Radiofrequency ablation</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec sec-type="intro">
      <title>INTRODUCTION</title>
      <p>The coexistence hepatocellular carcinoma (HCC) and renal cell carcinoma (RCC) is extremely rare, and only a few case reports could be found in the literature.<xref rid="B1" ref-type="bibr">1</xref></p>
      <p>Radiofrequency ablation (RFA) has been shown to be safe and successful for local tumor control in patients with HCC and is increasingly used for HCC patients.<xref rid="B2" ref-type="bibr">2</xref>,<xref rid="B3" ref-type="bibr">3</xref>,<xref rid="B4" ref-type="bibr">4</xref> Currently, RFA and cryoablation are considered alternatives to a partial nephrectomy in patients unable to undergo surgery.<xref rid="B5" ref-type="bibr">5</xref> These treatment options offer several benefits compared to a nephrectomy, including a lower complication rate, shorter hospital stay, less ischemic damage, and the potential for outpatient management of the patient.<xref rid="B5" ref-type="bibr">5</xref></p>
      <p>We present a case of synchronous HCC and RCC treated with RFA and a review of the literature.</p>
    </sec>
    <sec>
      <title>CASE REPORT</title>
      <p>A-53-year-old man visited our hospital with general weakness. He was referred to our hospital because of condition that suggested HCC, RCC, and alcoholic liver cirrhosis. His past medical history only included diabetes mellitus (DM). He has no family history of disease. The patient has a 30 pack-year smoking history and would drink so ju (a Korean distilled spirits), approximately 2-3 bottles daily for the previous 3 months. The serum bilirubin was 2.6 mg/dL, serum albumin was 2.9 g/dL, and prothrombin time (INR; International Normalized Ratio) was 1.26. A small amount of ascites was observed. Hepatic encephalopathy was not observed (Child-Pugh score 9, stage B). Abdominal contrast-enhanced computed tomography (CT) and magnetic resonance image (MRI) showed liver cirrhosis with 2.8 cm ill-defined mass in segment 2 of the liver and 1.9 cm hypervascular mass in left kidney. An enhancing mass, approximately 2.8 cm, without an apparent border in the arterial phase and washed out in delayed phase was noticed in S2 of the liver (<xref ref-type="fig" rid="F1">Fig. 1</xref>). A mass with a thickened smooth wall, approximately 1.9 cm, in the enhancing arterial phase in left kidney was noticed in the arterial phase in a CT image (<xref ref-type="fig" rid="F2">Fig. 2</xref>). These findings were compatible with double primary cancers of HCC and RCC. There was no evidence of lymph node or distant metastasis. In S2 of the liver, a hypervascular mass, approximately 2.8 cm was noticed in the T2 weighted image in the MRI and an approximate 1.9 cm mass in the left kidney was noticed in a T1 weighted image in the MRI (<xref ref-type="fig" rid="F3">Fig. 3</xref>). The serum alpha fetoprotein (AFP) was 6.93 ng/mL and the serum protein induced by vitamin K absence/antagonist-II (PIVIKA-II) was 23 mAU/mL. The HBsAg, Anti-HBs and Anti-HCV were all negative. Transarterial chemoembolization (TACE) was performed to treat the HCC. Two days after the TACE, the focal lipiodol uptake defect was noticed in follow up CT images and loco-regional treatment was recommended. No other significant abnormal hypermetabolic lesion suggesting malignancy was noticed on positron emission tomography-CT (PET-CT). Therefore, we performed RFAs to treat HCC and RCC. There was no significant complication after the procedure. One month later, follow-up CT images were taken. There was no evidence of recurrence (<xref ref-type="fig" rid="F4">Fig. 4</xref>).</p>
    </sec>
    <sec sec-type="discussion">
      <title>DISCUSSION</title>
      <p>To our knowledge, this is first report of a double primary HCC and RCC case that were both treated with RFA. Synchronous early primary cancers are rare. One study showed an incidence of 3.7% of synchronous cancers related to RCC.<xref rid="B1" ref-type="bibr">1</xref> Such malignancies include urological cancers, esophageal carcinomas, colorectal carcinomas, lung cancer, breast cancer, gynecological cancer, sarcoma and non-Hodgkin's lymphoma.<xref rid="B6" ref-type="bibr">6</xref> The occurrence of synchronous RCC and HCC is extremely rare.<xref rid="B1" ref-type="bibr">1</xref> HCC can be diagnosed from a CT image with a hypervascular mass in the arterial phase and washout in the portal venous or delayed phases.<xref rid="B7" ref-type="bibr">7</xref> The typical imaging characteristics of HCC on MRI are a large (&gt;2 cm) hyperintense lesion on T2-weighted images.<xref rid="B8" ref-type="bibr">8</xref> The spiral CT has significantly improved the imaging of renal masses by decreasing the volume averaging artifacts and respiratory misregistration artifacts and allowing image acquisition during optimal contrast enhancement.<xref rid="B9" ref-type="bibr">9</xref> Single- and multidetector CT have helped refine the diagnostic work-up of renal masses by allowing for image acquisition in various phases of renal enhancement after the intravenous administration of a single bolus of contrast material.<xref rid="B9" ref-type="bibr">9</xref> The renal parenchyma enhances homogeneously, allowing for the best opportunity for discrimination between the normal renal medulla and masses.<xref rid="B9" ref-type="bibr">9</xref> Most RCCs have the tendency to show isointensity to hypointensity on T1-weighted images and hyperintensity on T2-weighted images, although large RCCs tend to show heterogeneous signal intensity reflecting necrosis and hemorrhage.<xref rid="B10" ref-type="bibr">10</xref> Our specific CT and MRI findings were correctly indicated in the diagnostic criteria of the HCC and RCC. A non-invasive diagnosis was established by one imaging technique in nodules above 2 cm showing the HCC radiological hallmark and two coincidental techniques with nodules of 1-2 cm in diameter (CT, MRI and US-contrast). AFP levels were dropped from the diagnostic scheme.<xref rid="B7" ref-type="bibr">7</xref></p>
      <p>RFA has been shown safe and successful for local tumor control in patients with HCC and is increasingly used for HCC patients.<xref rid="B2" ref-type="bibr">2</xref>,<xref rid="B3" ref-type="bibr">3</xref>,<xref rid="B4" ref-type="bibr">4</xref> A single RFA treatment can necrotize approximately 3 cm area.<xref rid="B11" ref-type="bibr">11</xref> Currently, 3 or fewer tumors that are 3 cm or smaller are generally indicated for RFA.<xref rid="B11" ref-type="bibr">11</xref> For tumors larger than 3 cm in diameter, TACE is frequently performed first, followed by additional RFA.<xref rid="B12" ref-type="bibr">12</xref> Lipiodol TACE-preceded by RFA is aiming at the treatment of local residual and microsatellite lesions and micro-invasion and ensuring an accurate margin by lipiodol injection.<xref rid="B12" ref-type="bibr">12</xref> Blood flow promotes heat loss, and reducing or eliminating blood flow during the RFA procedure is known to increase the volume of the ablative zone.<xref rid="B13" ref-type="bibr">13</xref> Because HCCs are supplied almost entirely by the hepatic arteries, it seems reasonable to perform RFA after chemoembolization.<xref rid="B13" ref-type="bibr">13</xref> TACE and RFA were shown to be as effective as a liver resection for HCC in a recent study, with similar 1-, 3-, and 5-year overall and recurrence-free survival rates.<xref rid="B13" ref-type="bibr">13</xref></p>
      <p>In cases of RCC, radical or partial nephrectomy is the standard treatment for localized RCC.<xref rid="B14" ref-type="bibr">14</xref> Since it was first applied in 1997, renal RFA has become increasingly more accepted during the past few years.<xref rid="B14" ref-type="bibr">14</xref> RFA has been used as a nephron sparing alternative to a partial nephrectomy, with good early results.<xref rid="B14" ref-type="bibr">14</xref></p>
      <p>Recent report shows that RFA is an effective minimally invasive therapy for the treatment of cT1a RCC, yielding equivalent long-term oncologic outcomes to nephron-sparing surgery.<xref rid="B15" ref-type="bibr">15</xref> A characteristic of RFA is its cooling effect on the blood flow, which has a considerable effect on the outcome of RFA treatment.<xref rid="B16" ref-type="bibr">16</xref> The potential advantages of RFA over surgery include: having minimal invasiveness, avoiding damage to adjacent tissues, preserving the surrounding renal parenchyma, and reducing the complication rate, resulting in a shorter hospital stay.<xref rid="B17" ref-type="bibr">17</xref> But liver cirrhosis patients have an inhibitive risk to perform either a biopsy of the RCC or its resection. An RFA of malignant tumors has been a viable option in patients with primary and metastatic liver lesions, who are not candidates for surgery.<xref rid="B16" ref-type="bibr">16</xref></p>
      <p>In conclusion, coexistence of RCC and HCC is extremely rare. HCC and RCC can be diagnosed by the specific findings of a CT or MRI. Currently RFA has been used for the treatment of HCC or RCC with an appropriate indication. This is first report of synchronous HCC and RCC treated with RFA. Regularly scheduled follow-up is necessary to confirm the treatment results.</p>
    </sec>
  </body>
  <back>
    <fn-group>
      <fn fn-type="conflict">
        <p>None to declare.</p>
      </fn>
    </fn-group>
    <glossary>
      <title>Abbreviations</title>
      <def-list>
        <def-item>
          <term>RFA</term>
          <def>
            <p>Radio-Frequency Ablation</p>
          </def>
        </def-item>
        <def-item>
          <term>HCC</term>
          <def>
            <p>Hepatocellular Carcinoma</p>
          </def>
        </def-item>
        <def-item>
          <term>RCC</term>
          <def>
            <p>Renal Cell Carcinoma</p>
          </def>
        </def-item>
        <def-item>
          <term>CT</term>
          <def>
            <p>Computed Tomography</p>
          </def>
        </def-item>
        <def-item>
          <term>TACE</term>
          <def>
            <p>Transarterial Chemoembolization</p>
          </def>
        </def-item>
        <def-item>
          <term>DM</term>
          <def>
            <p>Diabetes Mellitus</p>
          </def>
        </def-item>
        <def-item>
          <term>MRI</term>
          <def>
            <p>Magnetic Resonance Image</p>
          </def>
        </def-item>
        <def-item>
          <term>AFP</term>
          <def>
            <p>Alpha Fetoprotein</p>
          </def>
        </def-item>
        <def-item>
          <term>PIVKA-II</term>
          <def>
            <p>Protein Induced by Vitamin K Absence/antagonist-II</p>
          </def>
        </def-item>
      </def-list>
    </glossary>
    <ref-list>
      <ref id="B1">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Garcia</surname>
              <given-names>JH</given-names>
            </name>
            <name>
              <surname>Coelho</surname>
              <given-names>GR</given-names>
            </name>
            <name>
              <surname>Cavalcante</surname>
              <given-names>FP</given-names>
            </name>
            <name>
              <surname>Valen&#xE7;a</surname>
              <given-names>JT</given-names>
              <suffix>Jr</suffix>
            </name>
            <name>
              <surname>Brasil</surname>
              <given-names>IR</given-names>
            </name>
            <name>
              <surname>Cesar-Borges</surname>
              <given-names>G</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Synchronous hepatocellular carcinoma and renal cell carcinoma in a liver transplant recipient: a case report</article-title>
          <source>Transplantation</source>
          <year>2007</year>
          <volume>84</volume>
          <fpage>1713</fpage>
          <pub-id pub-id-type="pmid">18165787</pub-id>
        </element-citation>
      </ref>
      <ref id="B2">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lencioni</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Loco-regional treatment of hepatocellular carcinoma</article-title>
          <source>Hepatology</source>
          <year>2010</year>
          <volume>52</volume>
          <fpage>762</fpage>
          <lpage>773</lpage>
          <pub-id pub-id-type="pmid">20564355</pub-id>
        </element-citation>
      </ref>
      <ref id="B3">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Guimaraes</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Uflacker</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Locoregional therapy for hepatocellular carcinoma</article-title>
          <source>Clin Liver Dis</source>
          <year>2011</year>
          <volume>15</volume>
          <fpage>395</fpage>
          <lpage>421</lpage>
          <pub-id pub-id-type="pmid">21689621</pub-id>
        </element-citation>
      </ref>
      <ref id="B4">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Germani</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Pleguezuelo</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Gurusamy</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Meyer</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Isgro</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Burroughs</surname>
              <given-names>AK</given-names>
            </name>
          </person-group>
          <article-title>Clinical outcomes of radiofrequency ablation, percutaneous alcohol and acetic acid injection for hepatocelullar carcinoma: a meta-analysis</article-title>
          <source>J Hepatol</source>
          <year>2010</year>
          <volume>52</volume>
          <fpage>380</fpage>
          <lpage>388</lpage>
          <pub-id pub-id-type="pmid">20149473</pub-id>
        </element-citation>
      </ref>
      <ref id="B5">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Heuer</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Gill</surname>
              <given-names>IS</given-names>
            </name>
            <name>
              <surname>Guazzoni</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Kirkali</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Marberger</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Richie</surname>
              <given-names>JP</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>A critical analysis of the actual role of minimally invasive surgery and active surveillance for kidney cancer</article-title>
          <source>Eur Urol</source>
          <year>2010</year>
          <volume>57</volume>
          <fpage>223</fpage>
          <lpage>232</lpage>
          <pub-id pub-id-type="pmid">19853989</pub-id>
        </element-citation>
      </ref>
      <ref id="B6">
        <label>6</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Papalampros</surname>
              <given-names>AE</given-names>
            </name>
            <name>
              <surname>Petrou</surname>
              <given-names>AS</given-names>
            </name>
            <name>
              <surname>Mantonakis</surname>
              <given-names>EI</given-names>
            </name>
            <name>
              <surname>Evangelou</surname>
              <given-names>KI</given-names>
            </name>
            <name>
              <surname>Giannopoulos</surname>
              <given-names>LA</given-names>
            </name>
            <name>
              <surname>Marinos</surname>
              <given-names>GG</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Coexistence of a colon carcinoma with two distinct renal cell carcinoma</article-title>
          <source>J Med Case Rep</source>
          <year>2011</year>
          <volume>5</volume>
          <fpage>134</fpage>
          <pub-id pub-id-type="pmid">21463521</pub-id>
        </element-citation>
      </ref>
      <ref id="B7">
        <label>7</label>
        <element-citation publication-type="journal">
          <collab>European Association For The Study Of The Liver</collab>
          <collab>European Organisation For Research And Treatment Of Cancer</collab>
          <article-title>EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma</article-title>
          <source>J Hepatol</source>
          <year>2012</year>
          <volume>56</volume>
          <fpage>908</fpage>
          <lpage>943</lpage>
          <pub-id pub-id-type="pmid">22424438</pub-id>
        </element-citation>
      </ref>
      <ref id="B8">
        <label>8</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Witjes</surname>
              <given-names>CD</given-names>
            </name>
            <name>
              <surname>Willemssen</surname>
              <given-names>FE</given-names>
            </name>
            <name>
              <surname>Verheij</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>van der Veer</surname>
              <given-names>SJ</given-names>
            </name>
            <name>
              <surname>Hansen</surname>
              <given-names>BE</given-names>
            </name>
            <name>
              <surname>Verhoef</surname>
              <given-names>C</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Histological differentiation grade and microvascular invasion of hepatocellular carcinoma predicted by dynamic contrast-enhanced MRI</article-title>
          <source>J Magn Reson Imaging</source>
          <year>2012</year>
          <volume>36</volume>
          <fpage>641</fpage>
          <lpage>647</lpage>
          <pub-id pub-id-type="pmid">22532493</pub-id>
        </element-citation>
      </ref>
      <ref id="B9">
        <label>9</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sheth</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Scatarige</surname>
              <given-names>JC</given-names>
            </name>
            <name>
              <surname>Horton</surname>
              <given-names>KM</given-names>
            </name>
            <name>
              <surname>Corl</surname>
              <given-names>FM</given-names>
            </name>
            <name>
              <surname>Fishman</surname>
              <given-names>EK</given-names>
            </name>
          </person-group>
          <article-title>Current Concepts in the Diagnosis and Management of Renal Cell Carcinoma: Role of Multidetector CT and Three-dimensional CT</article-title>
          <source>Radiographics</source>
          <year>2001</year>
          <volume>21</volume>
          <fpage>S237</fpage>
          <lpage>S254</lpage>
          <pub-id pub-id-type="pmid">11598260</pub-id>
        </element-citation>
      </ref>
      <ref id="B10">
        <label>10</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Shinmoto</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Yuasa</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Tanimoto</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Narimatsu</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Jinzaki</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Hiramatsu</surname>
              <given-names>K</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Small renal cell carcinoma: MRI with pathologic correlation</article-title>
          <source>J Magn Reson Imaging</source>
          <year>1998</year>
          <volume>8</volume>
          <fpage>690</fpage>
          <lpage>694</lpage>
          <pub-id pub-id-type="pmid">9626888</pub-id>
        </element-citation>
      </ref>
      <ref id="B11">
        <label>11</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ansari</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Andersson</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Radiofrequency ablation or percutaneous ethanol injection for the treatment of liver tumors</article-title>
          <source>World J Gastroenterol</source>
          <year>2012</year>
          <volume>18</volume>
          <fpage>1003</fpage>
          <lpage>1008</lpage>
          <pub-id pub-id-type="pmid">22416173</pub-id>
        </element-citation>
      </ref>
      <ref id="B12">
        <label>12</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Arii</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Sata</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Sakamoto</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Shimada</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Kumada</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Shiina</surname>
              <given-names>S</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Management of hepatocellular carcinoma: report of Consensus Meeting in the 45th Annual Meeting of the Japan Society of Hepatology</article-title>
          <source>Hepatol Res</source>
          <year>2010</year>
          <volume>40</volume>
          <fpage>667</fpage>
          <lpage>685</lpage>
          <pub-id pub-id-type="pmid">20633193</pub-id>
        </element-citation>
      </ref>
      <ref id="B13">
        <label>13</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yamakado</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Nakatsuka</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Takaki</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Yokoi</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Usui</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Sakurai</surname>
              <given-names>H</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Early-stage hepatocellular carcinoma: radiofrequency ablation combined with chemoembolization versus hepatectomy</article-title>
          <source>Radiology</source>
          <year>2008</year>
          <volume>247</volume>
          <fpage>260</fpage>
          <lpage>266</lpage>
          <pub-id pub-id-type="pmid">18305190</pub-id>
        </element-citation>
      </ref>
      <ref id="B14">
        <label>14</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gill</surname>
              <given-names>IS</given-names>
            </name>
          </person-group>
          <article-title>Minimally invasive nephron-sparing surgery</article-title>
          <source>Curr Opin Urol</source>
          <year>2003</year>
          <volume>13</volume>
          <fpage>179</fpage>
          <pub-id pub-id-type="pmid">12692437</pub-id>
        </element-citation>
      </ref>
      <ref id="B15">
        <label>15</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Olweny</surname>
              <given-names>EO</given-names>
            </name>
            <name>
              <surname>Park</surname>
              <given-names>SK</given-names>
            </name>
            <name>
              <surname>Tan</surname>
              <given-names>YK</given-names>
            </name>
            <name>
              <surname>Best</surname>
              <given-names>SL</given-names>
            </name>
            <name>
              <surname>Trimmer</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Cadeddu</surname>
              <given-names>JA</given-names>
            </name>
          </person-group>
          <article-title>Radiofrequency ablation versus partial nephrectomy in patients with solitary clinical T1a renal cell carcinoma: comparable oncologic outcomes at a minimum of 5 years of follow-up</article-title>
          <source>Eur Urol</source>
          <year>2012</year>
          <volume>61</volume>
          <fpage>1156</fpage>
          <lpage>1161</lpage>
          <pub-id pub-id-type="pmid">22257424</pub-id>
        </element-citation>
      </ref>
      <ref id="B16">
        <label>16</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Goldberg</surname>
              <given-names>SN</given-names>
            </name>
            <name>
              <surname>Gazelle</surname>
              <given-names>GS</given-names>
            </name>
          </person-group>
          <article-title>Radiofrequency tissue ablation: Physical principles and techniques for increasing coagulation necrosis</article-title>
          <source>Hepatogastroenterology</source>
          <year>2001</year>
          <volume>48</volume>
          <fpage>359</fpage>
          <lpage>367</lpage>
          <pub-id pub-id-type="pmid">11379309</pub-id>
        </element-citation>
      </ref>
      <ref id="B17">
        <label>17</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hines-Peralta</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Goldberg</surname>
              <given-names>SN</given-names>
            </name>
          </person-group>
          <article-title>Review of radiofrequency ablation for renal cell carcinoma</article-title>
          <source>Clin Cancer Res</source>
          <year>2004</year>
          <volume>10</volume>
          <fpage>6328S</fpage>
          <lpage>6334S</lpage>
          <pub-id pub-id-type="pmid">15448026</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
  <floats-group>
    <fig id="F1" orientation="portrait" position="float">
      <label>Figure 1</label>
      <caption>
        <p>A contrast-enhanced abdominal CT shows a 2.8 cm sized mass in segment 2 of the liver with enhancement during the arterial phase and washed out during the delayed phase. (A) Arterial phase. (B) Delayed phase.</p>
      </caption>
      <graphic xlink:href="cmh-20-306-g001"/>
    </fig>
    <fig id="F2" orientation="portrait" position="float">
      <label>Figure 2</label>
      <caption>
        <p>Contrast-enhanced abdominal CT shows a 1.9 cm sized mass in the mid-pole of the left kidney with enhancement during the arterial phase.</p>
      </caption>
      <graphic xlink:href="cmh-20-306-g002"/>
    </fig>
    <fig id="F3" orientation="portrait" position="float">
      <label>Figure 3</label>
      <caption>
        <p>(A) About 2.8 cm hyperintense mass in the S2 of the liver was examined in T2 weighted MRI. (B) About 1.9 cm hypointense mass in the mid pole of the left kidney was examined in T1 weighted MRI.</p>
      </caption>
      <graphic xlink:href="cmh-20-306-g003"/>
    </fig>
    <fig id="F4" orientation="portrait" position="float">
      <label>Figure 4</label>
      <caption>
        <p>(A) Follow-up abdominal CT shows a lipiodol uptake and RF ablated liver mass. (B) Follow-up abdominal CT shows a small hypodense RFA area in the left kidney during the delayed phase.</p>
      </caption>
      <graphic xlink:href="cmh-20-306-g004"/>
    </fig>
  </floats-group>
</article>
</pmc-articleset>
